Kornimate/medical-research-clean huggingface dataset:
evaluation of intracanal reinforcement with short composite post in upper primary incisors with severly carious teeth as in early childhood caries cases using randomized clinical trial

Conditions: Composite Post; Intracanal Reinfocement

Summary: severely damaged incisors may lead to difficulty in speech, decreased masticatory efficiency, abnormal tongue habits, subsequent malocclusions, and psychological and self-esteem problems. there are several methods mentioned in the literature for the restoration of severely decayed primary anterior teeth. the benefits of pulp therapy include: removing cavitations or defects to eliminate areas that are susceptible to caries; stopping the progression of tooth demineralization; restoring the integrity of tooth structure; preventing the spread of infection and preventing the shifting of teeth due to loss of tooth structure. the risks of pulp therapy include lessening the longevity of teeth by making them more susceptible to fracture as after removal of gross caries lesion and gaining access to the pulp the tooth become too weak, recurrent lesions, restoration failure, complications, and iatrogenic damage to adjacent teeth. there are different techniques can be used for gaining intracanal retention in primary teeth. one of these techniques is resin composite posts. composite post restorations have been in used in primary teeth from 1986. they yield satisfactory results when there is normal masticatory function, a balanced diet, and hygiene control. the evidence to support any method of intracanal reinforcement for restoring grossly broken down anterior teeth is presently lacking. this study aims to evaluate the intracanal reinforcement with short composite post in upper primary incisors versus no reinforcement.


Eligibility criteria:
inclusion criteria: * children criteria: * medically free. * cooperative patient. * age (3 - 5 years) incisors criteria: • upper primary incisors show large carious lesions. radiographic criteria: • no evidence of internal/external pathologic root resorption. exclusion criteria: * • uncooperative children. * children with systemic disease. * refusal of participation in the study.
periodic limb movement syndrome in patients with cerebral small vessel disease.

Conditions: Periodic Limb Movement Disorder; Cerebral Small Vessel Diseases; Cognitive Dysfunction

Summary: patients from 60 to 75 years old diagnosed with cerebral small vessel disease with no history of symptomatic stroke, brain tumor, traumatic brain injury, seizures and neurodegenerative or mental disorder will undergo overnight leg actigraphy and cardiorespiratory monitoring. those of them with apnea/hypopnea index under 5 will be enrolled. brain mri and cognitive assessment will be performed at baseline and in 1-year follow-up, sleep quality will be assessed at baseline with self-reported questionnaires. progression of cerebral small vessel disease markers and cognitive dysfunction will be compared between patients with high periodic limb movement index (the number of periodic limb movement ≥ 15 per hour of sleep) and controls (periodic limb movement index \< 15/h).


Eligibility criteria:
inclusion criteria: * diagnosis of a cerebral small vessel disease - assessed by mri. * ability to follow the procedures of the study, fluent russian language - assessed by self-report. exclusion criteria: * history of symptomatic stroke, brain tumor or traumatic brain injury - assessed by self-report and clinical history. * history of severe psychiatric comorbidities other than anxiety and depression, substance use disorder - assessed by self-report and clinical history. * significant visual loss (leading to difficulties with performing cognitive tasks) - assessed by self-report and clinical history. * presence of dementia - assessed by history and clinical examination. * movement disorders (e.g. tremor, dystonia etc.) leading to lower velocity of performing cognitive tasks against the clock - assessed by clinical examination. * obstructive sleep apnea syndrome - according to the criteria of international classification of sleep disorders iii. * restless legs syndrome - according to the criteria of the international restless legs syndrome study group. * current intake of neuroleptics, benzodiazepines, selective serotonin reuptake inhibitors - assessed by self-report and clinical history.

Keywords: aged cerebral small vessel disease cognitive dysfunction magnetic resonance imaging periodic limb movement disorder sleep disorder
innovative robotic gait trainer use to enable walking in children with cerebral palsy gmfcs iii and iv

Conditions: Cerebral Palsy

Summary: exploration to optimize mixed quantitative and qualitative methodology using multiple outcome measures in a randomized, cross-over trial structure comparing the effect of robotic gait training (rgt) group, and functional clinical therapy (fct) using each subject as their own control.

exploration to optimize mixed quantitative and qualitative methodology using multiple outcome measures in a randomized, cross-over trial structure comparing the effect of robotic gait training (rgt) group, and functional clinical therapy (fct) using each subject as their own control. the primary objective is to assess feasibility of the study design and device tolerability. specifically: * recruitment success (number screened, number eligible, number enrolled) where 80% of the recruitment target is reached. * attrition rates of less than 10% (i.e. ≥90% of participant's successfully complete assessments). * adherence for each participant: 80% of participants who complete assessments achieve the minimum target dose (i.e. approx. ≥30 hours of therapy in both study groups). * qualitative feedback from clinicians and patients/caregivers on device tolerability and study participation. secondary objectives will evaluate the distance a child can walk in two minutes using the two minute walk test (2mwt, 18) and will examine a more global impact of the use of this technology. data collected will include quality of gait, child or proxy chosen individualized goals, hypertonicity, contractures, and bone health.

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of cerebral palsy * gmfcs levels iii and iv * ages ≥2 to ≤12 years * ability to take steps with and/or without assistance * meet the trexo plus device size requirements * ability to follow instructions and signal pain, fear, or discomfort * ability to safely use the device at home as determined by the study team exclusion criteria: * lower limb or orthopedic surgery within 9 months prior to enrollment * botulinum toxin injections within 4 months prior to enrollment * serial casting within 3 months prior to enrollment * knee flexion contracture \> 20° * knee valgus \> 40° * hip subluxation \> 40 % migration percentage * uncontrolled movements that prevent transfer in and/or out of device * weight bearing restrictions * uncontrolled seizures * skin lesions in areas where the device straps would be attached * significant language barrier with parents and/or caregivers note: children with severe contractures will be unable to fit in the device and are therefore excluded from the study
avatrombopag for the treatment of thrombocytopenia in adults scheduled for a surgical procedure

Conditions: Thrombocytopenia

Summary: phase 3b open-label, multicenter study to evaluate the safety and efficacy of avatrombopag in subjects with thrombocytopenia scheduled for operations to critical sites or operations with a high risk of bleeding.

subjects will receive oral avatrombopag once daily for 5 days beginning on day 1, followed by a wait period prior to the procedure, which will occur on day 10 to 13. the follow-up period will include 2 visits; 7 days post-procedure and 30 days after last dose.

Eligibility criteria:
inclusion criteria: * men and women greater than or equal to 18 years of age; * a mean baseline platelet count between: * 50 × 10\^9/l and \<100 × 10\^9/l for non-chronic liver disease participants * 50 × 10\^9/l and \<75 × 10\^9/l for participants with chronic liver disease; * participant is scheduled to undergo operations to critical sites (eg, eye surgery, neurosurgery) or operations with a high risk of bleeding (eg, major abdominal surgery), or, in the opinion of the investigator, would otherwise require a pre-operative platelet transfusion to prevent bleeding exclusion criteria: * participant with a history of arterial or venous thrombosis within 6 months of baseline; * participant with known portal vein blood flow velocity rate \<10 cm/second or previous portal vein thrombosis within 6 months of baseline; * participant plans to have a platelet transfusion or plans to receive blood products containing platelets within 7 days of the baseline visit; * use of erythropoietin-stimulating agents; * participant has a known medical history of genetic prothrombotic syndromes; or * participant has abnormal hemoglobin levels or prothrombin time/international normalized ratio

Keywords: low platelet count itp
relationship between acoustic breath sounds and spirometry

Conditions: Asthma COPD

Summary: the goal of this clinical trial is to assess whether wheeze as assessed by a commercially available wheeze monitor is comparable to lung function as measured during a spirometry test. the main questions it aims to answer are whether measures of airflow obstruction (fev1, fev1/fvc, pef) correlate with wheeze score (tw/ttot%). participants consenting to take part will undergo wheeze measurement prior to and during a spirometry test and will be asked to complete a series of symptom questionnaires.


Eligibility criteria:
inclusion criteria: * consenting adult (aged 18-95) university hospitals birmingham patient's attending the lung function and sleep department (lf\&s) routinely as part of their standard clinical management pathway for lung function testing that includes spirometry assessments. * all patients irrespective of condition will be approached to participate. exclusion criteria: * subjects who are contraindicated to perform spirometry on the day of testing * subjects who cannot speak or read english * patients accessing non-adult services * subjects who are unable or do not wish to consent * patients with known or suspected restrictive lung disease
pilot study to evaluate mr-guided laser ablation of focal lesions in patients with medically refractory partial epilepsy

Conditions: Epilepsy

Summary: to investigate whether mr-guided laser induced thermal therapy in patients diagnosed with focal lesional epilepsy using the visualase thermal therapy system is both a feasible and safe minimally invasive technique for control of seizures in such patients.

in this study, we propose to evaluate a novel, thermal therapy and feedback system (visualase® thermal therapy system) as an alternative to surgical resection for the treatment of focal lesional epilepsy in patients that are considered high risk surgical candidates. this system includes the fda-cleared visualase cooled laser applicator system (vclas), which allows delivery of laser energy while the patient is being imaged by an mri unit. the visualase® system works via real-time mr thermal imaging (mrti) to provide information on the thermal dose delivered to the target, resulting in a more precise and controlled delivery which has heretofore not been possible with previous non-image guided laser technology. we hypothesize that the visualase system can be used in patients refractory to medication therapy in a minimally invasive procedure to destroy epileptogenic focal lesions in the brain.

Eligibility criteria:
inclusion criteria: * age 18 years or older at entry to protocol. * history of mri lesional-related epilepsy for at least one year. * failure to respond to more than 2 anti-epileptic drugs at adequate dose and duration. * candidate for resective epilepsy surgery. * considered healthy enough to undergo surgery with general anesthesia. * the patient has given written informed consent after the nature of the study and alternative treatment options have been explained. * must have 3 months of seizure frequency recorded prior to procedure. exclusion criteria: * presence of any non-mri compatible implanted electronic device. * presence of a metallic prosthetic or implant including artificial hips, knees, joints, or rods and screws. * active major depression * history of suicide attempts * history of non-epileptic behavioral spells
effects of renal transplantation on uraemic cardiomyopathy

Conditions: Cardiomyopathies

Summary: chronic kidney disease (ckd) is associated with a high risk of death and morbidity due to cardiovascular disease. much of this is caused by left ventricular disease characterised by abnormal muscle thickness and scaring. this process appears to start early in the course of ckd and causes heart failure and dangerous abnormal heart rhythms. previous work suggests that the process may be reversible by kidney transplantation but almost all of the studies are small, retrospective and lack scientific rigour. furthermore, they almost all use echocardiography, which is inaccurate in patients with ckd. the investigators plan to perform the first large, prospective, controlled, blind-analysed study using cardiac magnetic resonance imaging to determine whether ckd associated cardiomyopathy is reversed by kidney transplantation and if so, whether factors such as blood pressure and mediators of metabolic bone disease/fibrosis are important in effecting this change. greater understanding of the mechanisms responsible for ckd associated cardiomyopathy could lead to future strategies and treatments to improve the high cardiovascular mortality associated with this condition.


Eligibility criteria:
inclusion criteria: 1. patients registered on the kidney transplant waiting list at the university hospital birmingham nhs foundation trust. 2. ages over 18 years exclusion criteria 1. non-standard anti-rejection treatment, post transplant. 2. previous history of being unable to tolerate mri scanner. 3. contraindication to mri - eg metal fragments in ey
line: treatment patterns in postmenopausal women with hormone receptor positive breast cancer

Conditions: Local Advanced or Metastatic Postmenopausal Breast Cancer

Summary: this is the first study focused on features/stereotypes of the first and second-line treatment patterns in russia, comparison of different treatments, and determination of effective hormone treatment patterns in real-life practice with evaluation of pharmacoeconomic aspects. study line is designed for collection of data on clinical effectiveness of second-line hormone treatment and quality of life in patients with breast cancer(bc).

line: treatment patterns in postmenopausal women with hormone receptor positive breast cancer

Eligibility criteria:
inclusion criteria: * postmenopausal women with hormone receptor-positive breast cancer: * recurrence after the adjuvant hormone therapy; * or initially inoperable locally advanced or metastatic breast cancer progressed after the first line hormone therapy; * ability to read and write and complete questionnaires provision of written informed consent * patients who have already been prescribed therapy with the above-mentioned lines and who can continue on the prescribed therapy in the investigator's opinion according to his/her regular clinical practice and cure exclusion criteria: * as per study design, to ensure high validity of data and to obtain accurate information on real-life practice, * patients currently participating in other clinical studies will not be included in this study

Keywords: breast cancer, hormone positive,
imaging of corneal and crystalline by near infrared retro-illumination

Conditions: Eye Diseases

Summary: retroillumination photography is difficult. the reflections on the cornea and the lens are constant and prevent from obtaining a complete and clear image. study team have modified a slit lamp intended to photograph the anterior segment of the eye in retroillumination by using a light source in the near infrared (780 nm), and a process which eliminates the reflections.


Eligibility criteria:
inclusion criteria: * patient with corneal pathology, crystalline pathology, or pigmentary glaucoma with transilluminable iris. in case of bilateral disease, both eyes will be photographed * patient having received an instillation of eye drops to dilate the pupil of the eye to be photographed (or of both eyes). exclusion criteria: * major blepharospasm * poor or no pupillary dilation: patient with allergy or intolerance to eye drops used for pupillary dilation, refusal of pupillary dilation * pregnant or breastfeeding patient * person under legal protection

Keywords: pigmentary glaucoma crystalline pathology corneal pathology retroillumination infrared
a trial of thickened feeds to treat gastroesophageal reflux in children admitted after choking spell

Conditions: Apparent Life Threatening Event; Gastroesophageal Reflux; Aspiration

Summary: infants often present to the hospital with episodes of coughing, choking, gagging, change in muscle tone, and/or change in skin color, known as brief resolved unexplained event. many studies have tried to address why infants have these symptoms and if there is a way to prevent them from happening again. currently, there is no clear agreement on the most common cause of these symptoms or how to prevent them. some studies have suggested that gastroesophageal reflux can cause these symptoms. the investigators are conducting a study of infants who are admitted to boston children's hospital with episodes of coughing, choking, gagging, change in muscle tone, and/or change in skin color, symptoms that could be reflux. the investigators want to determine if these symptoms can be prevented by changing the way infants are fed, either by giving them a formula to treat reflux or by thickening their feeds to treat reflux. the goal of the study is to determine if different types of feeding interventions prevent infants from coming back to the hospital.


Eligibility criteria:
inclusion criteria: * patients less than 12 months of age who have been admitted to the hospital after brief resolved unexplained event exclusion criteria: * patients with any pre-existing significant medical diagnosis (congenital heart disease, known neurologic impairment with or without seizure disorder, other congenital anomalies) * patients with any prior hospitalization for brue * patients with food allergies such that they cannot be on a milk or rice based diet * any patient exclusively breastfed because change to a formula or adding thickening is not possible unless patients choose to pump breast milk and stop all nursing

Keywords: brief resolved unexplained event
alzheimer's disease and aging: therapeutic potential of estrogen

Conditions: Alzheimer's Disease

Summary: this study is designed to evaluate the potential beneficial effects of estrogen on cognitive function of women with alzheimer's disease.


Eligibility criteria:
* post menopausal women with alzheimer's disease * free of any major medical or neurological disease, * medically safe to be treated with estrogen.
the effect of instrumentation and obturation on postoperative pain in retreatment

Conditions: Endodontically Treated Teeth; Post Operative Pain

Summary: objectives: the aim of this study was to assess postoperative pain in prospective randomized clinical trial comparing reciproc or hand instrument and also different obturation techniques in one visit of endodontic retreatment. conventional root canal treatment was done to 45 patients who needed retreatment. all instruments used in this study are routinely used instrument in endodontic therapy. after completed root canal treatment, the patients asked the intense of post operative pain.

materials and metods: the study was included 45 patients (18-65 yrs old) who needed endodontic retreatment in mandibular premolar or molar without any symptoms. the teeth had been randomly assign into 3 groups according to the instrumentation or obturation techniques; hand files with lateral condensation, reciproc with lateral condensation, or reciproc with continuous condensation technique. retreatments had performed in a single visit. coronal restorations were removed, the gutta-percha were extracted using either reciproc or hand files. after, biochemical and mechanical praparation, the canals were filled with gutta-percha cones and ah plus sealer using the lateral condensation or continuous wave of obturation technique. participants were been asked to rate the incidence and intensity of the postoperative pain on a verbal rating scale 24h, 48h and 72h and 7 days after retreatment. all data were analyzed using (chi-square test, p=0,05)

Eligibility criteria:
inclusion criteria: * patients who had previosly done unacceptable root canal treatment on lower premolar or molar with no pain. no medication should be taken 10 days before treatment for any reason ( such as corticosteroid, antibiotics or analgesic ) exclusion criteria: * age less than 18 or over 65,pregnancy nonrestorable tooth other than lower molar or premolar tooth with more than 4mm periodontal pocket root with broken instrument or any post

Keywords: post operative pain, retreatment
efficacy of home-based treatment for breast cancer-related lymphedema

Conditions: Lymphedema Arm

Summary: the goal of this clinical trials is to explore the effectiveness of home-based iymphedema treatment and the differences between the home-based and outpatient treatment. the main question is to verify that home-based treatment is as effective as outpatient treatment. we set two groups in this study, comparing the volume of affected upper limb to see if home-based iymphedema treatment is valuable method.

secondary outcome measures: 1. core quality of life questionnaire (eortc qlq-c30), it included five functional measures (somatic function, role function, cognitive function, emotional function, social function), three symptom measures (fatigue, pain, nausea and vomiting), six individual measures (dysphagia, loss of appetite, sleep disturbance, constipation, diarrhea, financial hardship), and one patient self-assessment item (total health status). 2. breast cancer and lymphedema symptom experience index (bcle-sei).

Eligibility criteria:
inclusion criteria: 1. lymphedema appeared in the upper limb after breast cancer-related treatment, and compared with the healthy side, the edema dimension was more than 2cm. 2. age 18-75 years old; 3. edema stage ⅰ to ⅱ; exclusion criteria: 1. people with severe cognitive impairment; 2. bilateral lymphedema; 3. patients undergoing radiotherapy； 4. patients with uncontrolled tumors; 5. congestive heart failure and other comprehensive detumescence treatment contraindicated patients.

Keywords: lymphedema breast cancer manual therapy home-based therapy